TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3214958
Drug: Standard short-contact
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard short-contact dithranol therapy
Study: 31756059
Drug: Standard-dose bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard-dose bevacizumab (10 mg/kg 2-weekly)
Study: 31756059
Drug: Reduced-dose bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Reduced-dose bevacizumab (5 mg/kg 2-weekly)
Study: 22309046
Drug: Clopidogrel (0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (0.20 mg/kg/day)
Study: 16205095
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) therapy; mean duration: 8.8 (1.7) years
Study: 16205095
Drug: Untreated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Untreated group (no GH therapy)
Study: 8551492
Drug: Losartan potassium
Normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan potassium (50 mg titrated to 100 mg)
Study: 8551492
Drug: Felodipine ER
Normalized name: Felodipine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine ER (5 mg titrated to 10 mg)
Study: 396063
Drug: Saralasin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saralasin (both doses)
Study: 24266074
Drug: Sacral canal
Normalized name: Canalevia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacral canal injection
Study: 31486420
Drug: CO2-laser myringotomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2-laser myringotomy on the 3rd day of hospital treatment
Study: 31486420
Drug: CO2-laser myringotomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2-laser myringotomy on the 7th day of hospital treatment
Study: 19480558
Drug: Intranasal dosing
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dosing of PF-219061
Study: 17461981
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg (SIMVA)
Study: 17461981
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of simvastatin 40 mg and ezetimibe 10 mg (EZE/SIMVA)
Study: 17461981
Drug: No lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: No lipid-lowering drugs (NLLD)
Study: 8010332
Drug: Beta-carotene (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (300 mg daily for 30 days)
Study: 8010332
Drug: Wheat germ
Normalized name: Wheat Germ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat germ oil capsules (control group)
Study: 30293449
Drug: MSN (extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSN (extended-release morphine sulfate with sequestered naltrexone)
Study: 27847195
Drug: Augmented Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented Cognitive Behavioral Therapy (CBT)
Study: 19133873
Drug: 15 mg/day
Normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/day elemental zinc syrup for 10 weeks
Study: 19133873
Drug: Placebo syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo syrup without zinc for 10 weeks
Study: 11574498
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg gemeprost
Study: 9822168
Drug: Radiotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy alone (median dose 4470 cGy)
Study: 7664428
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (sedation and blood pressure control)
Study: 10423058
Drug: Medical and
Normalized name: allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen Medicated Patch [Stratagraft]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical and surgical therapy
Study: 2751284
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g azlocillin every 6 h
Study: 2751284
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g azlocillin every 8 h
Study: 73744
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no A.C.T.H. administration)
Study: 73744
Drug: Total-hip replacement
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total-hip replacement with A.C.T.H. administration
Study: 30950165
Drug: Antenatal milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal milk expression (AME) intervention involving demonstration and practice with a lactation consultant, reinforcement at weekly visits until delivery, and daily home practice.
Study: 22500884
Drug: Degarelix (240/80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Degarelix (240/80 mg)
Study: 28394498
Drug: Goserelin (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin (3.6 mg) plus Bicalutamide (50 mg)
Study: 23395281
Drug: Prednisone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (1 mg/kg/d, orally)
Study: 23395281
Drug: Allopurinol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (100 mg, thrice daily, orally)
Study: 16739846
Drug: Warming needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warming needle moxibustion plus western medicine
Study: 15119917
Drug: IVIG (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG (1 g/kg on 2 consecutive days)
Study: 15592696
Drug: External beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: External beam irradiation (EBI) combined with interstitial HDR brachytherapy boost (mean dose 18 Gy)
Study: 15592696
Drug: Sole brachytherapy
Normalized name: English sole
DrugBank: English sole (DB10904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sole brachytherapy (mean dose 28 Gy)
Study: 2661966
Drug: oral cyclical
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral cyclical combination of estradiol valerate and cyproterone acetate
Study: 2661966
Drug: percutaneous 17
Normalized name: PERCUTANEOUS INTRODUCER SET
Approvals — FDA: no, EMA: no, PMDA: no
Description: percutaneous 17 beta‐estradiol, supplemented by oral progesterone during the second year
Study: 3308164
Drug: percutaneous placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: percutaneous placebo cream
Study: 31138727
Drug: Atezolizumab-chemotherapy
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab-chemotherapy
Study: 31138727
Drug: Atezolizumab-bevacizumab-chemotherapy
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab-bevacizumab-chemotherapy
Study: 28365464
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU), mainly individual-based cognitive behavioural therapy (CBT)
Study: 23232827
Drug: Early steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early steroid (mometasone furoate 50 µg/nostril/d starting on postoperative day 1)
Study: 23232827
Drug: Late steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late steroid (mometasone furoate 50 µg/nostril/d starting on postoperative day 7)
Study: 23232827
Drug: Early steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early steroid
Study: 19487710
Drug: No hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No hormone therapy suspension (n = 567)
Study: 19487710
Drug: 1 month
Normalized name: LUPRON-PED 15MG (1 MONTH) SA INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 month hormone therapy suspension (n = 570)
Study: 19487710
Drug: 2 months
Normalized name: Elecare HMO 0-12 Months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 months hormone therapy suspension (n = 567)
Study: 17557039
Drug: Topical mesalazine
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical mesalazine alone
Study: 17557039
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with mesalazine plus symbiotic (zir fos)
Study: 14765315
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injection (50 units delivered via two 25-U injections of 0.25 ml each into the pancreatic sphincter)
Study: 14765315
Drug: Sham saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham saline injection (0.50 ml of saline injected into the duodenal lumen)
Study: 19801024
Drug: Percutaneous Coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous Coronary Intervention (PCI) plus Optimal Medical Therapy (OMT)
Study: 15121136
Drug: Overnight switch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overnight switch to oxcarbazepine monotherapy
Study: 15121136
Drug: Progressive switch
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive switch to oxcarbazepine monotherapy
Study: 11859850
Drug: Desogestrel-containing oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desogestrel-containing oral contraceptives
Study: 11887980
Drug: Progestagen-only preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progestagen-only preparations (150 microg desogestrel)
Study: 2938985
Drug: Levonorgestrel-containing oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel-containing oral contraceptives
Study: 9783333
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg dexamethasone once a day for 4 days
Study: 8148710
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration solution containing glucose
Study: 8148710
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration solution containing rice
Study: 8148710
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration solution containing glycine
Study: 8148710
Drug: Carbohydrate free
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate free solution
Study: 28833829
Drug: 18 F‐FDG‐PET‐guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 F‐FDG‐PET‐guided dose painting (DPBC or DPBN)
Study: 28833829
Drug: 18 F‐FDG‐PET-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 F‐FDG‐PET-guided dose painting (DPBC or DPBN)
Study: 21823283
Drug: Acupoint injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint injection desensitization with autoblood (AJA)
Study: 21823283
Drug: Medicine group
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicine group (Dexamethasone Acetate cream and Setastine Hydrochloride)
Study: 17958029
Drug: DPP-IV resistant
Normalized name: L-DPPG-Na
DrugBank: Sodium 1,2-Dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (DB14105)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPP-IV resistant GLP-1 analogues (e.g., exenatide)
Study: 17958029
Drug: DPP-IV inhibitors
Normalized name: Dipeptidyl peptidase 4 (DPP-4) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPP-IV inhibitors (gliptins)
Study: 17958029
Drug: Sitagliptin (first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (first DPP-IV inhibitor)
Study: 15266329
Drug: Tamoxifen treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen treatment (5-year duration)
Study: 15266329
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (hormone-receptor-negative tumours, no further therapy)
Study: 15266329
Drug: Chemotherapy-induced ovarian
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy-induced ovarian dysfunction (amenorrhoea)
Study: 7931480
Drug: Vinorelbine (VRL)
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinorelbine (VRL) administered by continuous infusion (CIV) at a maximum-tolerated dose (MTD) of 8 mg/m2 bolus plus 10 mg/m2/d for 4 days (total dose per cycle, 48 mg/m2)
Study: 7931480
Drug: Vinorelbine (VRL)
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinorelbine (VRL) at different dose levels (DL)
Study: 3126220
Drug: Chlorpheniramine, 4
Normalized name: Chlorpheniramine, 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine, 4 mg three times a day
Study: 22717726
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate 45 mg kg(‐1) in 100 ml of isotonic saline
Study: 20047523
Drug: Perceived oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perceived oral health
Study: 20047523
Drug: Perception of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perception of oral health
Study: 20047523
Drug: Relationship between
Normalized name: CYCLIZED P12 (PEPTIDE BOND BETWEEN THE CARBOXY AND AMINO-TERMINAL ENDS OF THE LINEAR PEPTIDE PSHISKYILRWRPK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relationship between gingival bleeding and perceived oral health
Study: 15994252
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no CPAP treatment)
Study: 12905750
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g propacetamol in 100 ml normal saline intravenously
Study: 12905750
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg dolantin intramuscularly
Study: 12905750
Drug: 1.6 g
Normalized name: GLYCERIN 1241.6 g in 1 L TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 g mannitose in 100 ml NS intravenously as placebo control to propacetamol
Study: 8913990
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (moderate dose of alcohol 0.56 g/kg)
Study: 8913990
Drug: Group AC
Normalized name: Menveo (Men-ACYW), group ACYW intramuscular solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group AC (moderate dose of alcohol 0.56 g/kg with expectancy challenge)
Study: 8913990
Drug: Group NT
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group NT (no treatment, no alcohol)
Study: 1487552
Drug: Pyrazinoylguanidine (PZG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrazinoylguanidine (PZG) 600 mg twice daily for 4 weeks
Study: 3897960
Drug: Cefoxitin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (30 mg/kg intravenously over 30 minutes, one hour before surgery, and 30 mg/kg over one hour, 3 hours, and 6 hours after initial infusion)
Study: 3897960
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no routine intra or postoperative antibiotics)
Study: 30577943
Drug: Increased frequency
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increased frequency of IPT‐A (twice per week)
Study: 30577943
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of fluoxetine
Study: 29388275
Drug: 150 min·wk‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 min·wk‐1 of aerobic exercise (low-dose)
Study: 29388275
Drug: 300 min·wk‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 min·wk‐1 of aerobic exercise (high-dose)
Study: 25218903
Drug: Ozone preconditioning
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone preconditioning (Major Auto-Hemotherapy, 35µg/ml)
Study: 10450276
Drug: Tetrabenazine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetrabenazine (mean dose = 57.9 mg/day, duration = mean 20.3 weeks)
Study: 10450276
Drug: Tetrabenazine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetrabenazine (mean dose = 57.9 mg/day)
Study: 17934156
Drug: Negative-pressure wound
Normalized name: Microcyn Negative-Pressure Wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative-pressure wound therapy (NPWT) delivered through the V.A.C. Therapy System (n = 77)
Study: 17934156
Drug: Standard moist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard moist wound therapy (MWT) (n = 85)
Study: 16503775
Drug: Topical cyclosporin
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporin 0.05%
Study: 14517597
Drug: Oral risedronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral risedronate 5 mg/day for 12 months
Study: 3018068
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (30 ml of 2.39 M, 6.17 g)
Study: 3018068
Drug: Aluminum-magnesium antacid
Normalized name: ALUMINUM/MAGNESIUM HYDROXIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum-magnesium antacid (30 ml equivalent to 71.7 mmol of in vitro buffer)
Study: 22375574
Drug: Small changes
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small changes weight loss program (3-month intervention with bi-weekly phone calls for 6 months)
Study: 15941977
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g of alcohol per day (control)
Study: 10339777
Drug: Etidronate therapy
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etidronate therapy (400 mg/d for 14 days with 76-day intervals, plus 500 mg of supplemental calcium per day)
Study: 8954030
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg aldosterone iv
Study: 2347114
Drug: 1% ciclopiroxolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% ciclopiroxolamine solution
Study: 7028051
Drug: 1% ciclopiroxolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% ciclopiroxolamine cream
Study: 7028051
Drug: 1% tolnaftate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% tolnaftate solution
Study: 3530834
Drug: 1% clotrimazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% clotrimazole cream
Study: 14972467
Drug: Genistein-rich extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genistein-rich extract (3 capsules daily for 6 months)
Study: 9134943
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% penciclovir cream
Study: 10302355
Drug: Sequential protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential protocol using anti-lymphocyte serum (ALS) followed by cyclosporine from the third post-graft month onwards
Study: 10302355
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with ALS alone
Study: 25023098
Drug: 9 mL
Normalized name: ethanol 6.9 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mL agitated saline solution with 1 mL air without the Valsalva maneuver (ASwoVM)
Study: 25023098
Drug: 9 mL
Normalized name: ethanol 6.9 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mL agitated saline solution with 1 mL air with the Valsalva maneuver (ASwVM)
Study: 25023098
Drug: 9 mL
Normalized name: ethanol 6.9 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mL agitated saline solution, 1 mL air and a drop of the patient's blood without the Valsalva maneuver (ASbwoVM)
Study: 25023098
Drug: 9 mL
Normalized name: ethanol 6.9 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mL agitated saline solution, 1 mL air and a drop of the patient's blood, with the Valsalva maneuver (ASbwVM)
Study: 17825122
Drug: Multi-faceted intervention
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-faceted intervention (educational/CBT workbook, educational visit to consultants, reminder system on medication charts)
Study: 10227804
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g IVIG/kg/month
Study: 10227804
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g IVIG/kg/month
Study: 10227804
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 g iv albumin/kg/month)
Study: 8693937
Drug: Concerns about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concerns about safety of oral contraceptives
Study: 28127204
Drug: LAM +
Normalized name: lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LAM + vaccine
Study: 26265560
Drug: CPAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP therapy with good adherence
Study: 19607951
Drug: Virosomal vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virosomal vaccine (Inflexal V)
Study: 19607951
Drug: Standard subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard subunit vaccine (Influvac)
Study: 7852064
Drug: Low-dose group,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose group, 50 mg elemental iron + 60 mg ascorbic acid in a multi‐vitamin daily
Study: 7852064
Drug: Usual-dose group,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual-dose group, 200 mg elemental iron daily
Study: 2682011
Drug: Ringer's lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's lactate solution plus 50 gm of albumin (group A)
Study: 2682011
Drug: Ringer's lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's lactate solution alone (group B)
Study: 1253701
Drug: Combined preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined preparation containing 250 mg clofibrate and 180 mg inositol nicotinate
Study: 1253701
Drug: Clofibrate alone
Normalized name: Clofibrate
DrugBank: Clofibrate (DB00636)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clofibrate alone in double doses
Study: 1253701
Drug: Combined preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined preparation (doubled dose)
Study: 1253701
Drug: Combined preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined preparation
Study: 29258812
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg bevacizumab with FOLFIRI